Last updated: August 26, 2026
FLOXIN in Dextrose 5% Plastic Container is an intravenous formulation of ofloxacin, a fluoroquinolone antibacterial. Its commercial trajectory is defined by mature-market erosion, broad generic substitution, limited hospital demand and the absence of meaningful current exclusivity. The product has little standalone revenue visibility because historical sales were generally reported within broader FLOXIN, ofloxacin or hospital-antibiotic categories rather than as a separate SKU.
The product’s economic value is now concentrated in residual institutional demand, formulation availability and supply reliability. It is not a growth pharmaceutical asset.
What is FLOXIN in Dextrose 5% Plastic Container?
FLOXIN in Dextrose 5% Plastic Container is an intravenous solution containing ofloxacin in 5% dextrose. The product was supplied in ready-to-use plastic containers for hospital administration. Ofloxacin is a racemic fluoroquinolone with activity against selected gram-negative and gram-positive organisms.
The formulation was positioned for patients requiring intravenous treatment or those unable to take oral medication. Ofloxacin was also marketed in oral tablets, creating a step-down pathway from intravenous to oral therapy.
| Attribute |
Product profile |
| Brand |
FLOXIN |
| Active ingredient |
Ofloxacin |
| Dosage form |
Intravenous infusion |
| Diluent |
Dextrose 5% |
| Container |
Plastic infusion container |
| Therapeutic class |
Fluoroquinolone antibacterial |
| Primary setting |
Hospital and institutional care |
| Original sponsor |
Ortho-McNeil/Janssen-associated U.S. commercial organization |
| Commercial status |
Mature, genericized and limited-current-market product |
| Principal substitutes |
Generic ofloxacin, ciprofloxacin, levofloxacin and other hospital antibacterials |
The product label includes warnings associated with fluoroquinolones, including tendinitis and tendon rupture, peripheral neuropathy, central nervous system effects, dysglycemia and other class risks. FDA safety communications have materially affected fluoroquinolone prescribing, particularly for uncomplicated infections where alternative therapies are available.[1,2]
When did FLOXIN lose market exclusivity?
FLOXIN lost practical market exclusivity after the expiration of the relevant ofloxacin composition and product protections and the entry of generic ofloxacin products. The commercial loss of exclusivity occurred years before the current market period.
The brand’s effective exclusivity was weakened by several factors:
- Ofloxacin became available through generic manufacturers.
- Hospital formularies shifted toward other fluoroquinolones, especially ciprofloxacin and levofloxacin.
- Intravenous therapy was increasingly selected according to institutional protocols, local resistance data and antimicrobial stewardship policies.
- FDA warnings narrowed the use of systemic fluoroquinolones in uncomplicated conditions.
No current commercial premium can reasonably be attributed to an active patent monopoly around the active ingredient. The relevant original-ofloxacin patent estate is historical rather than a present barrier to generic entry.
What patents protect FLOXIN in Dextrose 5% Plastic Container?
The current product does not appear to have a commercially meaningful active patent estate protecting ofloxacin itself or the standard intravenous ofloxacin-in-dextrose formulation.
Composition and formulation patents
The original active-ingredient protection for ofloxacin expired long ago. Any historical patents covering the compound, crystalline form, synthesis or pharmaceutical use would no longer provide a practical barrier to generic intravenous ofloxacin.
The Dextrose 5% presentation is also technically conventional. A ready-to-use infusion product may involve manufacturing controls, container-closure specifications, solution stability, particulate limits and sterilization processes. Those attributes can create quality and operational barriers, but they generally do not create durable patent exclusivity once the underlying drug is generic.
Method-of-use patents
No current, commercially important method-of-use patent is generally associated with the standard FLOXIN intravenous product. Historical indications covered susceptible bacterial infections, but broad antibacterial treatment claims are unlikely to support present-day exclusivity.
Manufacturing and intellectual-property barriers
The principal barriers are operational:
- Sterile manufacturing capacity
- Validated aseptic processing
- Container compatibility
- Stability through the labeled shelf life
- Low-volume economics
- FDA compliance for injectable products
- Reliable hospital distribution
These barriers can reduce the number of active suppliers, but they are not equivalent to patent exclusivity. A supplier may face meaningful regulatory and manufacturing costs while still competing in a non-exclusive market.
What is the FDA and Orange Book status of FLOXIN?
FLOXIN’s regulatory value is limited by age, generic availability and uncertain current commercial distribution. The product was approved as an ofloxacin antibacterial formulation, but the brand’s present status should be distinguished from the status of generic ofloxacin injections.
The FDA Orange Book is relevant for listed patents, therapeutic-equivalence determinations and discontinued-drug records. A discontinued brand product can remain historically visible in FDA records even when it is no longer actively marketed. Generic products may continue to receive regulatory recognition independently of the branded product.
| Regulatory issue |
Commercial implication |
| Original NDA history |
Establishes the branded product’s approval pathway |
| Generic approvals |
Support substitution and price competition |
| Listed patents |
No evident current barrier of commercial significance |
| Discontinued or inactive brand status |
Reduces brand pricing power |
| Injectable product requirements |
Maintain manufacturing complexity despite generic status |
| Fluoroquinolone safety labeling |
Restricts some prescribing and can reduce demand |
FDA labeling requires class-level safety warnings and indication-specific risk-benefit assessment. The label also emphasizes that antibacterial drugs should be used only for proven or strongly suspected bacterial infections.[1]
How many patents cover FLOXIN today?
No meaningful current patent count supports a premium franchise thesis for FLOXIN in Dextrose 5% Plastic Container. Historical patents may appear in legacy regulatory or patent records, but the relevant commercial question is whether enforceable rights can delay a generic injectable product. The answer is generally no for the standard ofloxacin molecule and conventional dextrose presentation.
A patent review should separate:
- Expired compound patents
- Expired formulation patents
- Manufacturing-process patents
- Container or packaging claims
- Use patents tied to narrow patient populations
- Patents covering unrelated ofloxacin dosage forms
Packaging or manufacturing patents, if any remain in a particular jurisdiction, would not necessarily block a competing generic that uses a different process or container.
Which companies compete with FLOXIN?
Competition comes from both direct generic ofloxacin suppliers and therapeutic substitutes.
Direct generic competition
Generic ofloxacin injection suppliers compete primarily on:
- Contract and group-purchasing prices
- Backorder performance
- Container configuration
- Concentration and fill volume
- Hospital formulary status
- Supply continuity
The market is more likely to contain a small number of active injectable suppliers than a large number of active tablet suppliers because sterile injectables have higher compliance and manufacturing costs.
Therapeutic competition
The main substitutes include:
- Ciprofloxacin injection
- Levofloxacin injection
- Ceftriaxone and other cephalosporins
- Piperacillin-tazobactam
- Carbapenems for selected severe infections
- Oral fluoroquinolones when the patient can tolerate oral therapy
Ofloxacin is disadvantaged against levofloxacin and ciprofloxacin in many hospital protocols because those products have stronger institutional familiarity, broader formulary presence or more established positioning for specific serious infections.
| Product |
Relative competitive position |
| Ofloxacin injection |
Mature, low-growth and limited formulary relevance |
| Ciprofloxacin injection |
Stronger hospital presence in selected gram-negative infections |
| Levofloxacin injection |
Broad institutional use and convenient IV-to-oral transition |
| Ceftriaxone injection |
High use in common hospital and emergency indications |
| Broad-spectrum beta-lactams |
Preferred in many severe or resistant infections |
What is the financial trajectory of FLOXIN?
The financial trajectory is a long-term decline from branded revenue to low-value generic or residual institutional sales.
Revenue phases
| Period |
Financial condition |
| Pre-generic period |
Brand pricing and physician familiarity supported revenue |
| Early generic period |
Rapid price and share erosion |
| Mature generic period |
Low margins, purchasing pressure and supplier rationalization |
| Current market phase |
Limited standalone revenue and possible discontinuation or intermittent supply |
The intravenous product likely generated less revenue than oral FLOXIN because the addressable market was restricted to hospitals and infusion settings. Its sales were also exposed to formulary substitution, antimicrobial stewardship and purchasing contracts.
No reliable public source reports standalone revenue for FLOXIN in Dextrose 5% Plastic Container. Public company filings generally aggregate older brands, hospital products or antibacterial portfolios. A precise product-level revenue estimate would therefore not be supportable from public information.
Margin pressure
The product’s economics are structurally weak:
- Active pharmaceutical ingredient costs are only one part of total cost.
- Sterile filling and quality testing add fixed costs.
- Hospitals exert substantial purchasing pressure.
- Product shortages can create temporary price increases but do not establish durable pricing power.
- Low annual volume can make continued production uneconomic.
- Generic competitors can replace brand demand without supporting brand-level royalties.
Financial performance is therefore more dependent on supply continuity and manufacturing utilization than on clinical differentiation.
What generic launch scenarios exist for FLOXIN?
The most likely commercial scenarios are:
Scenario 1: Stable low-volume generic supply
One or more suppliers continue production for hospitals with established demand. Prices remain low, and the product persists as a secondary formulary option.
Scenario 2: Supplier consolidation
A supplier exits because of low margins, quality costs or limited demand. Remaining manufacturers gain temporary share and may experience short-term pricing improvement.
Scenario 3: Product discontinuation
If demand falls below the minimum efficient manufacturing volume, suppliers discontinue the product. Hospitals substitute another fluoroquinolone or a non-fluoroquinolone injectable antibiotic.
Scenario 4: Temporary shortage-driven repricing
A manufacturing interruption can produce short-term scarcity. This is a supply event, not a return of brand exclusivity. FDA drug-shortage records and wholesaler availability would be the relevant indicators.[3]
Are there Paragraph IV challenges involving FLOXIN?
Paragraph IV litigation is unlikely to be commercially relevant today because the core ofloxacin protections are historical and generic competition has already been established. Paragraph IV challenges generally matter when a branded product has an active listed patent capable of delaying approval or launch. That condition does not characterize the mature FLOXIN intravenous market.
Any litigation involving a current generic supplier would more likely concern:
- Manufacturing quality
- Product liability
- Antitrust conduct
- Contract disputes
- Distribution or shortage issues
- A narrow process or formulation right
It would not normally involve a credible attempt to preserve broad brand exclusivity for standard intravenous ofloxacin.
What litigation and settlement agreements affect FLOXIN?
No major current settlement structure is central to the commercial outlook for FLOXIN in Dextrose 5% Plastic Container. Historical Hatch-Waxman activity may exist in the broader ofloxacin product record, but it has limited present value once the market has moved to mature generic competition.
A current diligence review should distinguish between:
- Litigation tied to oral ofloxacin
- Litigation tied to unrelated fluoroquinolones
- Product-liability cases involving the class
- Patent disputes involving specific generic manufacturers
- Proceedings that affect the intravenous product itself
Class-wide fluoroquinolone safety litigation can affect prescribing and liability reserves, but it does not restore patent protection or improve the product’s revenue trajectory.[2]
What is the biosimilar risk for FLOXIN?
Biosimilar risk is not applicable. Ofloxacin is a small-molecule chemical drug, not a biologic. The relevant competitive pathway is abbreviated new drug application approval under the Hatch-Waxman framework, not biosimilar approval under the Biologics Price Competition and Innovation Act.
Generic risk is high, while biosimilar risk is zero as a regulatory category.
How does FLOXIN compare with competing antibiotics?
FLOXIN has weaker commercial positioning than many competing hospital antibiotics.
| Metric |
FLOXIN IV |
Ciprofloxacin IV |
Levofloxacin IV |
| Market maturity |
Very mature |
Mature |
Mature |
| Generic competition |
High |
High |
High |
| Hospital familiarity |
Moderate to low |
High |
High |
| IV-to-oral convenience |
Available |
Strong |
Strong |
| Formulary breadth |
Limited in many systems |
Broad in selected indications |
Broad in selected indications |
| Growth outlook |
Declining or flat at best |
Stable in defined uses |
Stable in defined uses |
| Patent protection |
No meaningful current protection |
No meaningful current protection |
No meaningful current protection |
Antimicrobial stewardship has reduced indiscriminate fluoroquinolone use across the class. Hospitals increasingly select therapy based on resistance patterns, infection severity, renal function, adverse-event risk and total treatment cost.
What is the geographic coverage of FLOXIN?
The product’s commercial relevance is primarily jurisdiction-specific. U.S. demand depends on FDA-approved products, National Drug Code listings, wholesaler availability and hospital purchasing contracts. A product’s historical approval in the United States does not establish current marketing activity in Europe, Japan or other markets.
Outside the United States, ofloxacin products may remain available under different brand names, presentations or local manufacturers. The commercial opportunity is therefore fragmented by country and depends on local generic registration, procurement systems and fluoroquinolone prescribing restrictions.
What is the investment outlook for FLOXIN?
FLOXIN in Dextrose 5% Plastic Container should be assessed as a mature injectable generic or legacy-brand product, not as an innovation asset.
Potential value drivers are limited to:
- A temporary shortage
- A specialized hospital contract
- Manufacturing cost advantages
- Reliable supply in a constrained injectable category
- Portfolio bundling with other institutional medicines
The principal risks are:
- Continued volume decline
- Generic price compression
- Product discontinuation
- Safety-driven demand reduction
- Hospital substitution
- Manufacturing noncompliance
- Lack of standalone revenue visibility
The product is unlikely to support meaningful royalty income, premium valuation or a litigation-driven exclusivity thesis without evidence of a proprietary delivery system, an active jurisdiction-specific patent or a strategic supply agreement.
Key Takeaways
- FLOXIN in Dextrose 5% Plastic Container is an intravenous ofloxacin product supplied in 5% dextrose.
- Its active-ingredient and core product exclusivity are historical and no longer provide a meaningful commercial barrier.
- Generic substitution and hospital formulary competition determine market performance.
- Biosimilar risk does not apply because ofloxacin is a small-molecule drug.
- Current revenue is unlikely to be reported separately and should not be inferred from broader FLOXIN or antibacterial sales.
- The main value drivers are supply reliability, sterile-manufacturing capability and short-term shortage conditions.
- The most likely long-term outcomes are low-volume generic continuation, supplier consolidation or discontinuation.
FAQs About FLOXIN in Dextrose 5% Plastic Container
Is FLOXIN in Dextrose 5% Plastic Container still marketed in the United States?
The branded product has limited current commercial visibility. Generic ofloxacin injection, where available, is the more relevant market product.
Is intravenous ofloxacin protected by patents?
The original ofloxacin composition and broad product protections are historical. No broad, commercially significant patent barrier is generally associated with standard intravenous ofloxacin in dextrose.
Can a generic manufacturer launch without a Paragraph IV challenge?
Yes. Once relevant patents have expired, a generic applicant does not need to rely on a Paragraph IV certification to enter the market.
Does the product qualify for orphan-drug exclusivity?
There is no general basis to treat this standard intravenous antibacterial formulation as an orphan product. Its indications are broad infectious-disease uses rather than a narrowly defined rare disease.
What would increase the value of this product?
Value would require a supply-constrained market, a differentiated container or formulation, a durable hospital contract, or a manufacturing advantage that lowers cost while preserving reliable injectable supply.
References
- U.S. Food and Drug Administration. (2016). FDA updates warnings for oral and injectable fluoroquinolone antibiotics due to disabling side effects. https://www.fda.gov
- U.S. Food and Drug Administration. (2018). Fluoroquinolone antibacterial drugs: Drug safety communication. https://www.fda.gov
- U.S. Food and Drug Administration. (n.d.). Drug shortages. https://www.fda.gov/drugs/drug-safety-and-availability/drug-shortages
- U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations, Orange Book. https://www.fda.gov/drugsatfda
- DailyMed. (n.d.). Ofloxacin injection prescribing information. National Library of Medicine. https://dailymed.nlm.nih.gov
